News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE)’s Stake In Cellectis (ALCLS)’ Capital Is Welcomed By Its Shareholders


7/31/2014 11:03:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS--(BUSINESS WIRE)--Regulatory News:The Extraordinary General Shareholders’ Meeting of Cellectis (Alternext: ALCLS) was held on Thursday July 31, 2014 in Paris, at the Group’s headquarters . This meeting had been convened to take a decision on a planned 25,779,047 euros capital increase through the issuance of 2,786,924 new ordinary shares (corresponding to a total par value of 139,346.20 euros) and the suppression of shareholders’ preferential subscription rights in favor of Pfizer.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES